Nachrichten zur Corcept Therapeutics Inc. Aktie

Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -14.29% and -18.53%, respectively, for the quarter ended March 2021. Do the…

Corcept Therapeutics EPS beats by $0.01, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results

MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…

Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?

Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon...…

Insiderhandel: Chief Financial Officer verkauft Aktien von Corcept Therapeutics im Wert von 240.219$

Robb, Gary Charles - Vorstand - Tag der Transaktion: 2021-04-23...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Corcept Therapeutics im Wert von 181.037$

Swisher, Daniel N Jr - Aufsichtsrat - Tag der Transaktion: 2021-04-05...…

Insiderhandel: Chief Accounting Officer verkauft Aktien von Corcept Therapeutics im Wert von 597.030$

Lyon, Joseph Douglas - Vorstand - Tag der Transaktion: 2021-04-01...…

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

CORCEPT THERAPEUTICS INC: 10-K Report

10-K...…

Corcept Therapeutics EPS beats by $0.06, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Insiderhandel: Vorstand verkauft Aktien von Corcept Therapeutics im Wert von 101.249 $

Maduck, Sean - Vorstand - Tag der Transaktion: 2021-02-11...…

Insiderhandel: Vorstand verkauft Aktien von Corcept Therapeutics im Wert von 253.903 $

Maduck, Sean - Vorstand - Tag der Transaktion: 2021-02-16...…

Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal…

Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript

CORT earnings call for the period ending December 31, 2020....…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Corcept Therapeutics Q4 2020 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Chief Accounting Officer verkauft Aktien von Corcept Therapeutics im Wert von 729.570 $

Lyon, Joseph Douglas - Vorstand - Tag der Transaktion: 2021-02-03...…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Corcept Therapeutics Incorporated im Wert von 143.687 $

Swisher, Daniel N Jr - Aufsichtsrat - Tag der Transaktion: 2021-01-19...…

Biggest Price Target Changes For Friday

HC Wainwright & Co. boosted the price target on Corcept Therapeutics Incorporated (NASDAQ: CORT) from $22 to $32. Corcept…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors

MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…

Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group?

NEW YORK , Nov. 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO,…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the…

Corcept Therapeutics -5% after Q3 miss and lower guidance

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

CORCEPT THERAPEUTICS INC: 10-Q Report

10-Q...…

Corcept Therapeutics: Q3 Earnings Insights

Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Corcept Therapeutics EPS beats by $0.01, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Corcept Therapeutics Q3 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Director verkauft Aktien von Corcept Therapeutics im Wert von 88.301 $

Swisher, Daniel N Jr - Director - Tag der Transaktion: 2020-10-19...…

Why Corcept Therapeutics Soared 37% Higher in September

A patent decision on its cortisol therapy Korlym is expected to be rendered next month....…

Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…

Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately....…

Corcept Therapeutics Incorporated (CORT) Q2 2020 Earnings Call Transcript

CORT earnings call for the period ending July 31, 2020....…

CORCEPT THERAPEUTICS INC: 10-Q Report

10-Q...…

CORCEPT THERAPEUTICS INC: 8-K Report

8-K...…

Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will…

Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer

MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…